Thursday September 02, 11:00Baobab Resources identifies distinct ore domain at Tete’s South Zone
Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.
FULL ARTICLE ►
Thursday September 02, 08:15Indonesia edges closer toward uranium mining and nuclear power
After nearly five decades of national debate on the issue, Indonesia's central government may finally be ready to develop a national nuclear policy, which may lead to domestic uranium mining.
FULL ARTICLE ►
Wednesday September 01, 01:25Green Dragon Gas reports significant growth as China’s thirst for energy continues
China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today.
In the company's interim results, [...]
FULL ARTICLE ►
Patheon is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon's technologies and services range from pre-clinical development to manufacturing a full array of dosage forms.
Patheon narrows first quarter loss as restructuring shows effect
TSX- listed Patheon Inc reduced its pretax loss substantially in the first quarter as a result of restructuring measures and cost reductions taking effect, while revenues were down compared to the prior year largely as a result of the stronger US dollar against its other major sales currencies.
Revenue in the seasonally weakest quarter to end-January fell 10 4 percent to US$147.2 million, a 2.9 opercent fall in local currencies. The company narrowed its pretax loss from continuing operations to US$2.1 million from US$11.4 million incurred in the previous first quarter. It made an operating profit of US$3.9 million compared with a US$4.0 million loss a year earlier.
Last month, Patheon rejected the unsolicited approach by JLL Patheon Holdings LLC, an affiliate of private equity group JLL Partners Inc, to buy the shares in Patheon it does not already own at US$2.00 apiece, as it substantially undervalued the company, its earnings potential and future growth prospects.
Patheon provides pharmaceutical manufacturing and packaging services
Register here to be notified of future Patheon Inc articles.
Investors interested in Patheon Inc recently viewed
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
